An ongoing Phase III trial of Genentech, Inc. 's Tecentriq (atezolizumab) in patients who experienced early recurrence of triple-negative breast cancer after prior therapy could provide a pathway to confirming the PD-L1 inhibitor’s benefit in first-line TNBC, a current accelerated approval indication facing the threat of withdrawal.
On 27 April, the Food and Drug Administration’s Oncologic Drugs Advisory Committee will kick off three days of meetings on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?